Literature DB >> 1679802

Infection in orthopaedic implants.

P J Sanderson1.   

Abstract

The infection rate in hip prostheses should be less than 1.0% but in other joints is higher probably because of proximity to the skin surface and less experience in joint design. The organisms causing hip implant infection are Staphylococcus aureus 35%, S. epidermidis 15%, coliforms 25%, and anaerobes and others 25%; in other joints there may be a higher incidence of staphylococci. Clinical diagnosis is difficult since symptoms, X-rays and scans do not distinguish infection from loosening, but the erythrocyte sedimentation rate (ESR) moderately rises in infection. Treatment of deep infection by antibiotics alone is unlikely to succeed, but suppression of infection in patients unsuited to operation is possible. Surgeons should be encouraged to aspirate from the affected joint to obtain a bacteriological diagnosis; in the absence of this procedure broad spectrum antibiotics with good activity against S. aureus and S. epidermidis are required. Antibiotics must penetrate the membrane which forms in many patients at the implant or cement/bone interface but there is no evidence as to which antibiotics do so best. For prophylaxis there are three areas of uncertainty: (1) does antibiotic-impregnated cement provide additional effect to systemic antibiotics, since antibiotics can be found in the wound fluid after operation and gentamicin remains at the interface for many months?; (2) what proportion of late infections are haematogenous and do they demand prophylaxis for dental and surgical procedures?; (3) should greater protection from spread of staphylococci for the patient's skin and carrier sites be considered?

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679802     DOI: 10.1016/0195-6701(91)90043-8

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  19 in total

1.  Risk infection factors in the total hip replacement.

Authors:  M Fernández Arjona; F Gómez-Sancha; F Peinado Ibarra; R Herruzo Cabrera
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

2.  [The infected implant. Part 1: bacteriology].

Authors:  U Geipel; M Herrmann
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

3.  Murine immune response to a chronic Staphylococcus aureus biofilm infection.

Authors:  Ranjani Prabhakara; Janette M Harro; Jeff G Leid; Megan Harris; Mark E Shirtliff
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

4.  The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials.

Authors:  H C Vogelyl; W J Dhertl; A Fleer; A J Verboutl
Journal:  Eur J Orthop Surg Traumatol       Date:  1996-05

5.  [Results before and after introduction of perioperative antibiotic prophylaxis in hip joint prostheses treatment of geriatric patients].

Authors:  W Kaiser; V Gulielmos; H Hausmann; S Ghalehasadi
Journal:  Unfallchirurgie       Date:  1996-08

6.  The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts. An in vitro study.

Authors:  Aasis Unnanuntana; Lindsay Bonsignore; Mark E Shirtliff; Edward M Greenfield
Journal:  J Bone Joint Surg Am       Date:  2009-11       Impact factor: 5.284

7.  Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus.

Authors:  Ranjani Prabhakara; Janette M Harro; Jeff G Leid; Achsah D Keegan; Megan L Prior; Mark E Shirtliff
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

8.  Development of a Novel and Rapid Antibody-Based Diagnostic for Chronic Staphylococcus aureus Infections Based on Biofilm Antigens.

Authors:  Janette M Harro; Mark E Shirtliff; William Arnold; Jennifer M Kofonow; Chad Dammling; Yvonne Achermann; Kristen Brao; Javad Parvizi; Jeff G Leid
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

9.  [Prophylactic antibiotherapy in hip arthroplasty. Cohort study].

Authors:  M Garrote-Garrote; J A Del-Moral-Luque; A Checa-García; J F Valverde-Cánovas; C Campelo-Gutiérrez; J Martínez-Martín; A Gil-de-Miguel; G Rodríguez-Caravaca
Journal:  Rev Esp Quimioter       Date:  2018-03-14       Impact factor: 1.553

10.  Ultrasonically enhanced vancomycin activity against Staphylococcus epidermidis biofilms in vivo.

Authors:  J C Carmen; B L Roeder; J L Nelson; B L Beckstead; C M Runyan; G B Schaalje; R A Robison; W G Pitt
Journal:  J Biomater Appl       Date:  2004-04       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.